ClinicalTrials.gg
Active, not recruitingNCT03992404PATTERNUpdated Oct 20, 2026

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

A Phase 3 interventional study of NT 201 and Placebo in Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury, sponsored by Merz Pharmaceuticals GmbH. Active, not recruiting at 71 sites in 15 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
603
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 908 studies in Brain Injuries, Traumatic with a site in United States — 211 open to participants now, 249 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Enrollment
18th of 649
603 · median 50
Started
2019
with 52 others
Phase 3
26 of 908
2 open now
Primary completion
2025-06
later than 24 of 248 live
Registered
544th of 908
by date

Among the 908 studies in Brain Injuries, Traumatic with a site in United States, this one is the 18th largest by enrollment of the 649 interventional ones that give a count, is one of 53 that started in 2019, is one of 26 in phase 3, reaches primary completion later than 24 of the 248 other live ones, and was the 544th registered.

Brain Injuries, Traumatic

1,722 studies on the registry are indexed under Brain Injuries, Traumatic; 448 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

211 of the 908 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Brain Injuries, Traumatic studies recruiting now, 122 (43%) set no upper age limit and 120 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 908 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.

The following 4 to 5 treatment cycles will investigate the safety and tolerability of treatment with NT 201 (botulinum toxin) when administered in doses between 400 and 800 Units (Open Label Extension Period). All participants will receive the treatment and the dose will depend on whether only lower limb spasticity or combined upper and lower limb spasticity are treated.

03

Conditions studied

  • Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male subject ≥ 18 years and ≤ 85 years at screening
  • Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury
  • Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus
  • Modified Ashworth Scale-Bohannon [MAS] score of 2 or 3 points in the ankle plantar flexor of the target lower limb (supine position, knee extended)
  • Minimum passive range of motion in ankle of the target lower limb (supine position, knee extended): 10°dorsiflexion and 20°plantarflexion
  • At least 4 months since last botulinum neurotoxin [BoNT] injection for treatment of spasticity or any other condition
  • For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an:
  • [aPTT] ≤ 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or
  • International normalized ratio [INR] value of ≤ 2.5 (subjects on coumarins or other anticoagulants monitored by INR)

Exclusion criteria

Exclusion Criteria:

  • Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert Eaton syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study
  • Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity
  • Body weight \< 50 kg
  • Severe atrophy of the target limb muscles
  • Previous, ongoing or planned treatments of spasticity with intrathecal baclofen
  • Previous, ongoing, or planned treatments of spasticity in the target lower limb with any of the following procedures: Surgical Intervention; Alcohol or phenol block; Muscle afferent block
  • Physiotherapy or use of orthoses or splints at the target limb initiated less than 4 weeks before screening or expected to change during the double blind phase of the study
  • Current or planned treatment with parenterally administered drugs that interfere with neuromuscular transmission (e.g. intrathecal baclofen, tubocurarine type muscle relaxants used in anesthesia), or local anesthetics in the treated region within 2 weeks prior to screening
  • Infection or inflammation at the injection sites
  • Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory tract infections, or compromised respiratory function as per investigator's clinical judgment
  • Pregnancy (as verified by a positive pregnancy test) or breast feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
603 participants (actual)

Study arms

  • Experimental
    NT 201 (IncobotulinumtoxinA, Xeomin)

    Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb. Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.

    Drug: NT 201

  • Placebo comparator
    Placebo

    Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb. Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.

    Drug: NT 201 · Drug: Placebo

Interventions

  • DrugNT 201

    Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

    Also known as: IncobotulinumtoxinA, Incobotulinumtoxin A, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins

  • DrugPlacebo

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

06

What researchers measure

Primary outcomes

  1. Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6

    The MAS is a 6-grade scale

    Time frame: Baseline to week 4-6

  2. Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6

    The GICS s a 9-grade scale

    Time frame: Week 4-6

  3. Occurrence of treatment emergent adverse events [TEAEs] in the Main Period

    Time frame: Baseline to week 12

Secondary outcomes

  1. Change from Study Baseline in Goal Attainment Scale [GAS] at Week 6

    The GAS is a 6-grade scale

    Time frame: Baseline to week 6

  2. Global Impression of Change Scale (GICS) assessed by the study subject at Week 4 to 6

    The GICS s a 9-grade scale

    Time frame: Week 4-6

  3. Global Impression of Change Scale (GICS) assessed by the caregiver at Week 4 to 6

    The GICS s a 9-grade scale

    Time frame: Week 4-6

07

Study locations

71 sites
  • Physical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479
    Birmingham, Alabama 35233, United States
  • University of Arkansas for Medical Sciences, Merz investigational site #0010481
    Little Rock, Arkansas 72205, United States
  • Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center; Merz investigational site #0010184
    Downey, California 90242, United States
  • New England institute for clinical research; Merz Investigational Site #0010441
    Stamford, Connecticut 06905, United States
  • Nova Clinical Research, Merz investigational site #0010474
    Brandenton, Florida 34209, United States
  • Brooks Rehabilitation Clinical Integration and Research, Merz investigational site #0010483
    Jacksonville, Florida 72204, United States
  • Sarasota Memorial Health Care System, Rehabilitation Medicine, Merz investigational site #0010478
    Sarasota, Florida 34239, United States
  • Neurology Center of New England P.C., Merz investigative site #0010476
    Foxborough, Massachusetts 02035, United States
  • Howard A. Rusk Rehabilitation Center; Merz investigational site #0010283
    Columbia, Missouri 65203, United States
  • Icahn School of Medicine at Mount Sinai, Neurology Department, Merz Investigational Site #0010191
    New York, New York 10029, United States
  • Weill Cornell Medical Center, Department of Rehabilitation Medicine; Merz Investigational Site #0010440
    New York, New York 10065, United States
  • University of Pittsburgh Medical Center, Physical Medicine & Rehabiliation, Merz Investigational Site #0010211
    Pittsburgh, Pennsylvania 15213, United States
  • UT Southwestern Medical Center, Department of Physical Medicine & Rehabilitation, Merz investigational site #0010082
    Dallas, Texas 75390-9055, United States
  • University of Texas Health Science Center McGovern, Medical School Department of PM&R; merz investigational site #0010183
    Houston, Texas 77030, United States
  • Medical College of Wisconsin,Department of PM&R, Merz Investigational Site #0010237
    Milwaukee, Wisconsin 53226, United States
  • CHU Brugmann Neurology; Merz investigational site #0320015
    Brussels, 1020, Belgium
  • UCL Bruxelles, Physical Medicine & Rehabilitation Department, Merz Investigational Site #0320013
    Brussels, 1200, Belgium
  • UZ Leuven Pellenberg campus; Merz investigational site #0320014
    Pellenberg, 3212, Belgium
  • UCL Mont Godinne, Physical Medicine & Rehabilitation Department; Merz Investigational Site #0320008
    Yvoir, 5530, Belgium
  • Glenrose Rehabilitation Hospital, Merz investigational site #0010195
    Edmonton, T5G 0B7, Canada
  • Neurology and Physiotherapy Skopalikova, Merz Investigational Site #4200049
    Brno, 61500, Czechia
  • University Hospital Ostrava; Neurology Departement, Merz investigational site #4200024
    Ostrava, 708 52, Czechia
  • Pardubice Regional Hospital; Merz investigational site #4200025
    Pardubice, 530 03, Czechia
  • Raymond Poincaré University Hospital, Service de MPR Pôle Handicap-Rééducation, Merz Investigational site #00330018
    Garches, 92380, France
  • CHU Lille/Hôpital Swynghedauw; investigational site # 0330045
    Lille, 59000, France
  • Pôle Saint-Hélier; Merz investigational site #0330024
    Rennes, 35000, France
  • Institut Universitaire de Readaptation Clemenceau, Physical Medicine / Rehabilitation Medecine, Merz Investigational site # 0330063
    Strasbourg, 67000, France
  • Rangueil Hospital-University Hospital Center (CHU) of Toulouse, Médecine physique et de réadaptation, Merz investigational site #0330025
    Toulouse, 31059, France
  • Uniklinik RWTH Aachen, Neurologie, Merz Investigational Site #0490191
    Aachen, 52074, Germany
  • Neurologie Bewegt; Merz Investigational site #0490378
    Berlin, 10627, Germany
  • University of Bonn Medical Center, Department of Neurodegenerative disease, Merz investigational site #0490390
    Bonn, 53127, Germany
  • Heinrich Heine University Duesseldorf, Department of Neurology; Merz Investigational Site #0490071
    Düsseldorf, 40225, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Merz Investigational site #0490079
    Hamburg, 20246, Germany
  • DKD HELIOS Medical Center, Fachbereich Neurologie, Merz Investigational Site #0490081
    Wiesbaden, 65191, Germany
  • Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Merz Investigational Site #0490302
    Würzburg, 97080, Germany
  • Petz Hospital, Neurology, Merz Investigational Site #0360010
    Győr, 9024, Hungary
  • St.Damjan Hospital, Kisvarda; Merz investigational site #0360019
    Kisvárda, 4600, Hungary
  • University of Szeged, Department of Neurology, Merz investigational site #0360008
    Szeged, 6725, Hungary
  • Azienda Ospedaliera Universitaria Ospedali Riuniti Di Foggia; Merz Investigational Site #0390018
    Foggia, 71122, Italy
  • IRCCS Ospedale Policlinico S. Martino, U.O.Complessa Riabilitazione e Rieducazione Funzionale; Merz investigational site #0390020
    Genova, 16132, Italy
  • Ospedale Maggiore della Carita, Dipartimento di Medicina fisica e Riabilitativa, Merz Investigational Site #0390017
    Novara, 28100, Italy
  • Ospedale Alfredo Fiorini, UOSD Neurologia Universitaria; Merz Investigational site #0390022
    Terracina, 04019, Italy
  • Specjalistyczna Praktyka Lekarska Dr. n. med Stanisław Ochudło, Merz Investigational Site #0480077
    Katowice, 40-097, Poland
  • Specjalistyczne Gabinety Sp z o.o., Merz Investigational Site #0480059
    Krakow, 30-539, Poland
  • NeuroKlinika Gabinet Lekarski Prof Andrzej Bogucki, Merz Investigational Site #0480101
    Lodz, 90-640, Poland
  • Indywidualna Praktyka Lekarska dr. hab. Med. Anna Szczepanska-Szerej, Merz Investigational Site #0480096
    Lublin, 20-582, Poland
  • Filia 7 Centrum Kompleksowej Rehabilitacji Sp. z o.o., Merz Investigational Site #0480100
    Warsaw, 01-518, Poland
  • Projekt Samodzielni Sp z o.o., Merz Investigational Site #0480099
    Warsaw, 02-121, Poland
  • Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Merz Investigational Site #0480023
    Warsaw, 02-957, Poland
  • Mazowiecki Szpital Brodnowski, Merz investigational site #0480064
    Warsaw, 03-242, Poland
  • Neuryt Diagnostyka I Terapia Neurologiczna, Merz investigational site #0480106
    Wroclaw, 50-305, Poland
  • Federal State Budgetary Educational Institution of Higher Education "Krasnoyarsk State Medical University n.a. Professor V.F. Voino-Yasenetskiy of Ministry Healthcare of Russian Federation", Merz Investigational Site #0070306
    Krasnoyarsk, 660049, Russia
  • State Autonomous Institution of Healthcare of Moscow City "Moscow Scientific and Practical Centre of Medical Rehabilitation, Regenerative and Sports Medicine of Moscow City Healthcare Department", Merz Investigational Site #0070011
    Moscow, 105005, Russia
  • Federal State Autonomous Institution "National Medical Research Centre "Treatment and Rehabilitation" of the Ministry of Health of the Russian Federation, Neurology department, Merz Investigational Site # 0070305
    Moscow, 125367, Russia
  • Federal State Budgetary Institution "National Medical Research Centre of Psychiatry and Neurology n.a. V.M. Bekhterev" of the Ministry of Healthcare of the Russian Federation, Merz Investigational Site #0070009
    Saint Petersburg, 195119, Russia
  • University Hospital Bratislav, 2nd Dept. of Neurology, Merz Investigational Site # 4210005
    Bratislava, 83305, Slovakia
  • Neurologicka klinika, Fakultna nemocnica Trnava; Merz investigational site #4210009
    Trnava, 917 01, Slovakia
  • Hospital Universitario Juan Ramón Jiménez, Merz Investigational Site #0340037
    Huelva, 21005, Spain
  • Hospital Universitario La Paz, Merz Investigational Site #0340007
    Madrid, 28046, Spain
  • Hospital Universitari Mútua de Terrassa, Merz Investigational Site #0340003
    Terrassa, 08221, Spain
  • University Hospital of Bern, Center of Parkinson's diseases and Movement disorders (ZfPB), Merz investigational site #0410015
    Bern, 3010, Switzerland
  • HFR Fribourg - Hôpital Cantonal, Department of Rehabilitation, Merz Investigational site #0410014
    Meyriez, 3280, Switzerland
  • CRR, Mee Suva (Clinique romande de réadaptation), Merz investigational site #0410016
    Sion, 1950, Switzerland
  • Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, MC "Neuron", Merz Investigational Site #3800018
    Kharkiv, 61000, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine; Merz Investigational Site #3800019
    Kharkiv, 61000, Ukraine
  • Lviv regional clinical hospital; Merz investigational site # 3800020
    Lviv, 79010, Ukraine
  • Rivne City Hospital 2, Department of Clinical Neurology and Neurorehabilitation; Merz investigational site #3800016
    Rivne, 33001, Ukraine
  • NPE "Regional Clinical Centre of Neurosurgery and Neurology" Transcarpathian Regional Council; Merz investigational site #3800014
    Uzhhorod, 88018, Ukraine
  • Cambridge University Hospitals NHS Foundation Trust; Merz Investigational Site 0440023
    Cambridge, CB2 0QQ, United Kingdom
  • Royal Devon and Exeter Foundation Trust Hospital, Department of Neurology, Merz Investigational Site #0440047
    Exeter, EX2 5DW, United Kingdom
  • The Walton Centre NHS Foundation Trust; Neuroscience Research Centre; Merz Investigational site #0440004
    Liverpool, L9 7LJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jun 2025, 69 months.

Of 30 phase 3 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 69. This study's 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jun 20, 2019
StartActual
Sep 16, 2019
Primary completionActual
Jun 19, 2025
CompletionEst.
Apr 2027
Results delay requested
Jun 17, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03992404
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Sep 16, 2019
Primary completion
Jun 19, 2025
Completion
Apr 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Merz Medical Expert
study director · Merz Pharmaceuticals GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: incobotulinumtoxinA

Start the discussion